To include your compound in the COVID-19 Resource Center, submit it here.

MannKind, Sanofi deal

MannKind granted Sanofi exclusive, worldwide rights to develop and commercialize Afrezza to treat adults with Type I and II diabetes. MannKind will receive $150 million in cash up

Read the full 282 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE